Table of Contents
Leukemia Research and Treatment
Volume 2013, Article ID 275760, 14 pages
Review Article

The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias

Department of Hematology, Oncology and Molecular Medicine, Upper Health Institute, Viale Regina Elena 299, 00161 Rome, Italy

Received 1 February 2013; Revised 30 April 2013; Accepted 14 May 2013

Academic Editor: Monique den Boer

Copyright © 2013 Ugo Testa and Elvira Pelosi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The development of the genetic studies on acute myeloid leukemias (AMLs) has led to the identification of some recurrent genetic abnormalities. Their discovery was of fundamental importance not only for a better understanding of the molecular pathogenesis of AMLs, but also for the identification of new therapeutic targets. In this context, it is essential to identify AML-associated “driver” mutations, which have a causative role in leukemogenesis. Evidences accumulated during the last years indicate that activating internal tandem duplication mutations in FLT3 (FLT3-ITD), detected in about 20% of AMLs, represents driver mutations and valid therapeutic targets in AMLs. Furthermore, the screening of FLT3-ITD mutations has also considerably helped to improve the identification of more accurate prognostic criteria and of the therapeutic selection of patients.